Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas

23 May 2016

Abstract excerpt

Abstract Purpose: Alteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade gliomas (PLGGs), and mTOR activation has been documented in the majority of these tumors. We investigated combinations of MEK1/2, BRAFV600E and mTOR inhibitors in gliomas carrying specific genetic alterations of the MAPK pathway. Experimental Design: We used human glioma lines containing BRAFV600E (adult high-grade:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Glioma Diagnosis and Treatment
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27217440
DOI: 10.1158/1078-0432.ccr-15-1101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF Status in Personalizing Treatment Approaches for Pediatric GliomasPMID 27217440Read ↗

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System TumorsSemantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.Semantic proximity Read ↗

Targeted therapy for BRAFV600E malignant astrocytoma.Semantic proximity Read ↗

Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.Semantic proximity Read ↗

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.Semantic proximity Read ↗

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Semantic proximity Read ↗

Beyond Base Camp: Promise and Pitfalls of PI3K/mTOR Inhibition in Pediatric High- Grade GliomasSemantic proximity Read ↗

Targeting BRAF in pediatric brain tumors.Semantic proximity Read ↗

Targeted Therapy Win in BRAF-Mutant Gliomas.Semantic proximity Read ↗

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.Semantic proximity Read ↗

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.